Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31396085,m/,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,445.20,12429,DB00275,Olmesartan
,31396085,m/,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,148.90,12430,DB00275,Olmesartan
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,451.40,12431,DB00275,Olmesartan
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,154.30,12432,DB00275,Olmesartan
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,295.80,12433,DB00275,Olmesartan
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,205.10,12434,DB00275,Olmesartan
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,298.90,12435,DB00275,Olmesartan
,31396085,m/z,The mass transition ion pairs were followed in negative ion mode as m/z 445.20 → 148.90 for Olmesartan; m/z 451.40 → 154.30 for Olmesartan D6 and m/z 295.80 → 205.10 for hydrochlorothiazide; m/z 298.90 → 206.30 for hydrochlorothiazide 13C D2.,Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS/MS and Its Application Through Bioequivalence Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31396085/),,206.30,12436,DB00275,Olmesartan
,31823090,percentage relative bioavailability,"In vivo pharmacokinetic study of olmesartan and azelnidipine conducted on human volunteers against Rezaltas® 10/8 mg tablet showed percentage relative bioavailability of 106.12 and 470.82%, respectively.",Chronological Delivery of Antihypertensive Drugs in Bilayered Core-in-Cup Buccoadhesive Tablets: In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31823090/),%,106.12,38646,DB00275,Olmesartan
,31823090,percentage relative bioavailability,"In vivo pharmacokinetic study of olmesartan and azelnidipine conducted on human volunteers against Rezaltas® 10/8 mg tablet showed percentage relative bioavailability of 106.12 and 470.82%, respectively.",Chronological Delivery of Antihypertensive Drugs in Bilayered Core-in-Cup Buccoadhesive Tablets: In Vitro and In Vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31823090/),%,470.82,38647,DB00275,Olmesartan
,30986085,bioavailability,Olmesartan medoxomil (OM) is a hydrophobic antihypertensive drug with low bioavailability (26%) and is known to have adverse effects such as celiac disease and enteropathy.,Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30986085/),%,26,42117,DB00275,Olmesartan
,24666338,activated partial th,"Eleven hours post overdose extracorporeal elimination was implemented as the patient developed worsening coagulopathy with an elevated international normalized ratio of 11 IU, an activated partial thromboplastin time of 115 s, and had renal impairment with a creatinine of 158 μmol/L.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),s,115,53236,DB00275,Olmesartan
,24666338,peak serum dabigatran level,"This patient developed a peak serum dabigatran level of 1560 ng/ml, 11 h postoverdose.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ng] / [ml],1560,53237,DB00275,Olmesartan
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],58.1,53238,DB00275,Olmesartan
,24666338,clearance,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),[ml] / [h],31.9,53239,DB00275,Olmesartan
,24666338,extraction ratio,"Clearance of dabigatran via continuous veno-venous hemodiafiltration was calculated, using both the recovery and A-V pair methods, with a mean clearance of 58.1 and 31.9 ml/h, respectively, and a calculated mean extraction ratio of 0.2.",Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24666338/),,0.2,53240,DB00275,Olmesartan
,29453084,Cmax,"In vivo pharmacokinetic study of olmesartan loaded solid lipid nanoparticles revealed higher Cmax of 1610 ng/mL, higher AUC of 15492.50 ng/mL and increased relative bioavailability by almost 2.3 folds compared to marketed formulation.",Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453084/),[ng] / [ml],1610,55484,DB00275,Olmesartan
,29453084,AUC,"In vivo pharmacokinetic study of olmesartan loaded solid lipid nanoparticles revealed higher Cmax of 1610 ng/mL, higher AUC of 15492.50 ng/mL and increased relative bioavailability by almost 2.3 folds compared to marketed formulation.",Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453084/),[ng] / [ml],15492.50,55485,DB00275,Olmesartan
,28116656,particle,"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation were found to be 140 ± 10.34 nm, 0.07 ± 0.016, and -21.43 ± 2.33 mV, respectively.","Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28116656/),nm,140,60913,DB00275,Olmesartan
,28116656,polydispersity index (PDI),"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation were found to be 140 ± 10.34 nm, 0.07 ± 0.016, and -21.43 ± 2.33 mV, respectively.","Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28116656/),mv,0.07,60914,DB00275,Olmesartan
,28116656,zeta potential,"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation were found to be 140 ± 10.34 nm, 0.07 ± 0.016, and -21.43 ± 2.33 mV, respectively.","Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28116656/),mv,-,60915,DB00275,Olmesartan
,28116656,zeta potential,"The particle size, polydispersity index (PDI), and zeta potential of optimized formulation were found to be 140 ± 10.34 nm, 0.07 ± 0.016, and -21.43 ± 2.33 mV, respectively.","Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28116656/),mv,21.43,60916,DB00275,Olmesartan
,31616143,oral bioavailability,"The intention of this work was to load olmesartan medoxomil (OLM), a sparsely water soluble antihypertensive bioactive with low oral bioavailability (26%), into PEGylated bilosomes (PBs) for augmenting its transdermal delivery.","Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),%,26,66435,DB00275,Olmesartan
,31616143,EE%,"The optimal formula (PB15) showed spherical vesicles with EE% of 72.49±0.38%, PS of 559.30±10.70 nm, PDI of 0.57±0.15, ZP of -38.35±0.65 mV and Q6h of 59.60±0.24%.","Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),%,72.49,66436,DB00275,Olmesartan
,31616143,PDI,"The optimal formula (PB15) showed spherical vesicles with EE% of 72.49±0.38%, PS of 559.30±10.70 nm, PDI of 0.57±0.15, ZP of -38.35±0.65 mV and Q6h of 59.60±0.24%.","Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),,0.57,66437,DB00275,Olmesartan
,31616143,Q6h,"The optimal formula (PB15) showed spherical vesicles with EE% of 72.49±0.38%, PS of 559.30±10.70 nm, PDI of 0.57±0.15, ZP of -38.35±0.65 mV and Q6h of 59.60±0.24%.","Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),%,59.60,66438,DB00275,Olmesartan
,31616143,deformability index,PB15 showed higher deformability index (28.39±5.71 g) compared to traditional bilosomes (5.88±0.90 g) and transethosomes (14.94±0.63 g).,"Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),g,28.39,66439,DB00275,Olmesartan
,31616143,deformability index,PB15 showed higher deformability index (28.39±5.71 g) compared to traditional bilosomes (5.88±0.90 g) and transethosomes (14.94±0.63 g).,"Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),g,5.88,66440,DB00275,Olmesartan
,31616143,deformability index,PB15 showed higher deformability index (28.39±5.71 g) compared to traditional bilosomes (5.88±0.90 g) and transethosomes (14.94±0.63 g).,"Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),g,14.94,66441,DB00275,Olmesartan
,31616143,relative bioavailability,"As well, the relative bioavailability of PB15 was found to be 235.04%.","Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31616143/),%,235.04,66442,DB00275,Olmesartan
,22880942,weight-adjusted apparent total body clearance (CL/F),"In Groups 2, 3, and 4, the weight-adjusted apparent total body clearance (CL/F) of olmesartan medoxomil was 0.100 ± 0.034, 0.062 ± 0.020, and 0.072 ± 0.022 L/h/kg, respectively, and the weight-adjusted apparent volume of distribution (Vd/F) was 0.32 ± 0.16, 0.33 ± 0.14, and 0.49 ± 0.23 L/kg, respectively.",Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22880942/),[l] / [h·kg],0.100,75299,DB00275,Olmesartan
,22880942,weight-adjusted apparent total body clearance (CL/F),"In Groups 2, 3, and 4, the weight-adjusted apparent total body clearance (CL/F) of olmesartan medoxomil was 0.100 ± 0.034, 0.062 ± 0.020, and 0.072 ± 0.022 L/h/kg, respectively, and the weight-adjusted apparent volume of distribution (Vd/F) was 0.32 ± 0.16, 0.33 ± 0.14, and 0.49 ± 0.23 L/kg, respectively.",Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22880942/),[l] / [h·kg],0.062,75300,DB00275,Olmesartan
,22880942,weight-adjusted apparent total body clearance (CL/F),"In Groups 2, 3, and 4, the weight-adjusted apparent total body clearance (CL/F) of olmesartan medoxomil was 0.100 ± 0.034, 0.062 ± 0.020, and 0.072 ± 0.022 L/h/kg, respectively, and the weight-adjusted apparent volume of distribution (Vd/F) was 0.32 ± 0.16, 0.33 ± 0.14, and 0.49 ± 0.23 L/kg, respectively.",Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22880942/),[l] / [h·kg],0.072,75301,DB00275,Olmesartan
,22880942,weight-adjusted apparent volume of distribution (Vd/F),"In Groups 2, 3, and 4, the weight-adjusted apparent total body clearance (CL/F) of olmesartan medoxomil was 0.100 ± 0.034, 0.062 ± 0.020, and 0.072 ± 0.022 L/h/kg, respectively, and the weight-adjusted apparent volume of distribution (Vd/F) was 0.32 ± 0.16, 0.33 ± 0.14, and 0.49 ± 0.23 L/kg, respectively.",Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22880942/),[l] / [kg],0.32,75302,DB00275,Olmesartan
,22880942,weight-adjusted apparent volume of distribution (Vd/F),"In Groups 2, 3, and 4, the weight-adjusted apparent total body clearance (CL/F) of olmesartan medoxomil was 0.100 ± 0.034, 0.062 ± 0.020, and 0.072 ± 0.022 L/h/kg, respectively, and the weight-adjusted apparent volume of distribution (Vd/F) was 0.32 ± 0.16, 0.33 ± 0.14, and 0.49 ± 0.23 L/kg, respectively.",Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22880942/),[l] / [kg],0.33,75303,DB00275,Olmesartan
,22880942,weight-adjusted apparent volume of distribution (Vd/F),"In Groups 2, 3, and 4, the weight-adjusted apparent total body clearance (CL/F) of olmesartan medoxomil was 0.100 ± 0.034, 0.062 ± 0.020, and 0.072 ± 0.022 L/h/kg, respectively, and the weight-adjusted apparent volume of distribution (Vd/F) was 0.32 ± 0.16, 0.33 ± 0.14, and 0.49 ± 0.23 L/kg, respectively.",Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22880942/),[l] / [kg],0.49,75304,DB00275,Olmesartan
,11451213,Steady-state elimination half-life,"Steady-state elimination half-life values were also longer in elderly (12.8 h) and very elderly patients (16.5 h) compared with young patients (10.6 and 12.3 h, respectively).","Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451213/),h,12.8,88232,DB00275,Olmesartan
,11451213,Steady-state elimination half-life,"Steady-state elimination half-life values were also longer in elderly (12.8 h) and very elderly patients (16.5 h) compared with young patients (10.6 and 12.3 h, respectively).","Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451213/),h,16.5,88233,DB00275,Olmesartan
,11451213,Steady-state elimination half-life,"Steady-state elimination half-life values were also longer in elderly (12.8 h) and very elderly patients (16.5 h) compared with young patients (10.6 and 12.3 h, respectively).","Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451213/),h,10.6,88234,DB00275,Olmesartan
,11451213,Steady-state elimination half-life,"Steady-state elimination half-life values were also longer in elderly (12.8 h) and very elderly patients (16.5 h) compared with young patients (10.6 and 12.3 h, respectively).","Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451213/),h,12.3,88235,DB00275,Olmesartan
,29700766,oral bioavailability,Olmesartan medoxomil (OM) is an antihypertensive drug with poor water solubility and low oral bioavailability (28.6%).,Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),%,28.6,98575,DB00275,Olmesartan
,29700766,span,"OM nanosuspension was prepared by antisolvent-precipitation-ultrasonication method and characterized regarding particle size (122.67 ± 5.03 nm), span value (1.40 ± 0.51), and zeta potential (- 46.56 ± 1.20 mV).",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),,1.40,98576,DB00275,Olmesartan
,29700766,zeta potential,"OM nanosuspension was prepared by antisolvent-precipitation-ultrasonication method and characterized regarding particle size (122.67 ± 5.03 nm), span value (1.40 ± 0.51), and zeta potential (- 46.56 ± 1.20 mV).",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),m,-,98577,DB00275,Olmesartan
,29700766,zeta potential,"OM nanosuspension was prepared by antisolvent-precipitation-ultrasonication method and characterized regarding particle size (122.67 ± 5.03 nm), span value (1.40 ± 0.51), and zeta potential (- 46.56 ± 1.20 mV).",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),m,46.56,98578,DB00275,Olmesartan
,29700766,tensile strength,"The optimum formula (FDF1) showed 0.43 ± 0.02 kg/mm2 tensile strength, 20.50 ± 2.12 s disintegration time, and 87.53 ± 2.50 and 95.99 ± 0.25% OM dissolved after 6 and 10 min, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),[kg] / [mm2],0.43,98579,DB00275,Olmesartan
,29700766,disintegration time,"The optimum formula (FDF1) showed 0.43 ± 0.02 kg/mm2 tensile strength, 20.50 ± 2.12 s disintegration time, and 87.53 ± 2.50 and 95.99 ± 0.25% OM dissolved after 6 and 10 min, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),s,20.50,98580,DB00275,Olmesartan
,29700766,disintegration time,"The optimum formula (FDF1) showed 0.43 ± 0.02 kg/mm2 tensile strength, 20.50 ± 2.12 s disintegration time, and 87.53 ± 2.50 and 95.99 ± 0.25% OM dissolved after 6 and 10 min, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),%,95.99,98581,DB00275,Olmesartan
,29700766,Cmax,"The Cmax value increased significantly from 66.62 ± 14.95 to 179.28 ± 23.96 ng/mL for market tablet and FDF1, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),[ng] / [ml],66.62,98582,DB00275,Olmesartan
,29700766,Cmax,"The Cmax value increased significantly from 66.62 ± 14.95 to 179.28 ± 23.96 ng/mL for market tablet and FDF1, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),[ng] / [ml],179.28,98583,DB00275,Olmesartan
,29700766,AUC0-72,"Similarly, the AUC0-72 value significantly increased from 498.36 ± 217.46 to 1083.67 ± 246.32 ng h/mL for market tablet and FDF1, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),[h·ng] / [ml],498.36,98584,DB00275,Olmesartan
,29700766,AUC0-72,"Similarly, the AUC0-72 value significantly increased from 498.36 ± 217.46 to 1083.67 ± 246.32 ng h/mL for market tablet and FDF1, respectively.",Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),[h·ng] / [ml],1083.67,98585,DB00275,Olmesartan
,29700766,Relative bioavailability,Relative bioavailability of FDF1 was 209.28%.,Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29700766/),%,209.28,98586,DB00275,Olmesartan
,27487480,Peff,Morin showed the highest Peff value 13.8 ± 0.34 × 10-6 cm/s in jejunum than ileum (p < .01) at 100 µM with absorption enhancement of 1.31-fold together with enhanced (p < .01) secretory transport of 6.27 ± 0.27 × 10 -6 cm/s in Caco-2 monolayer cells.,In vitro and in vivo effects of morin on the intestinal absorption and pharmacokinetics of olmesartan medoxomil solid dispersions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487480/),[cm] / [s],13.8,100847,DB00275,Olmesartan
,27487480,secretory transport,Morin showed the highest Peff value 13.8 ± 0.34 × 10-6 cm/s in jejunum than ileum (p < .01) at 100 µM with absorption enhancement of 1.31-fold together with enhanced (p < .01) secretory transport of 6.27 ± 0.27 × 10 -6 cm/s in Caco-2 monolayer cells.,In vitro and in vivo effects of morin on the intestinal absorption and pharmacokinetics of olmesartan medoxomil solid dispersions. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27487480/),[cm] / [s],6.27,100848,DB00275,Olmesartan
,32888102,bioavailability,Olmesartan medoxomil (OLM) an antihypertensive molecule with poor solubility and poor bioavailability (26% when taken orally) was selected as a model drug.,"Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32888102/),%,26,115934,DB00275,Olmesartan
,32888102,bioavailability,In-vivo pharmacokinetic studies performed in Sprague-Dawley rats reflected superior bioavailability (201.60%) with a significant increase in the Cmax with short Tmax through amorphization of OLM.,"Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32888102/),%,201.60,115935,DB00275,Olmesartan
,20091278,bioavailability (BA),"OLM has a low bioavailability (BA), approximately 26% in humans, due to its low water solubility and efflux by drug resistance pumps in the gastrointestinal tract.",Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091278/),%,26,119610,DB00275,Olmesartan
,20091278,T(max),"In an oral absorption study in rats, SMEDDS formulation brought faster absorption compared to suspension, showing a T(max) value of 0.2 hr.",Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20091278/),h,0.2,119611,DB00275,Olmesartan
,27535556,CL/F,"The mean values of CL/F and V/F of olmesartan in the patients were 0.31565 L/h and 44.5162 L, respectively.","Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27535556/),[l] / [h],0.31565,132297,DB00275,Olmesartan
,27535556,V/F,"The mean values of CL/F and V/F of olmesartan in the patients were 0.31565 L/h and 44.5162 L, respectively.","Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27535556/),l,44.5162,132298,DB00275,Olmesartan
,18583274,flow rate,The mobile phase consisted of water-methanol- acetonitrile(14:60:26) with a flow rate of 0.22 ml/min.,[High-performance liquid chromatography-mass spectrometry for determining olmesartan in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18583274/),[ml] / [min],0.22,143738,DB00275,Olmesartan
,27355963,emulsification time,"All formulae also showed rapid emulsification time (15.46 ± 1.34-24.17 ± 1.47 s), good optical clarity (98.33% ± 0.16%-99.87% ± 0.31%) and high drug loading efficiency (96.41% ± 1.20%-99.65% ± 1.11%).","Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27355963/),s,15.46,156741,DB00275,Olmesartan
,27355963,emulsification time,"All formulae also showed rapid emulsification time (15.46 ± 1.34-24.17 ± 1.47 s), good optical clarity (98.33% ± 0.16%-99.87% ± 0.31%) and high drug loading efficiency (96.41% ± 1.20%-99.65% ± 1.11%).","Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27355963/),s,24.17,156742,DB00275,Olmesartan
,17554345,maximal time,"After oral administration, in animals and humans, it achieves a maximal blood drug concentration within a maximal time of approximately 2 h.","Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554345/),h,2,162052,DB00275,Olmesartan
,17554345,half-life,"His half-life is approximately 13 h, which makes it suitable for once-daily administration.","Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17554345/),h,13,162053,DB00275,Olmesartan
,34301030,zeta potential (ζP,"Among these formulations, ONS4 was regarded as the optimized formulation with particle size (487 nm), PDI (0.386), zeta potential (ζP = -18.1 mV), entrapment efficiency (EE = 91.2%) and drug loading (DL = 0.88%).",Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301030/),m,18.1,172002,DB00275,Olmesartan
,34301030,entrapment efficiency (EE,"Among these formulations, ONS4 was regarded as the optimized formulation with particle size (487 nm), PDI (0.386), zeta potential (ζP = -18.1 mV), entrapment efficiency (EE = 91.2%) and drug loading (DL = 0.88%).",Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301030/),%,91.2,172003,DB00275,Olmesartan
,34301030,surface area,"In addition, a nanosized porous morphology was detected for this optimized system with NS surface area of about 63.512 m2/g, pore volume and pore radius Dv(r) of 0.149 cc/g and 15.274 Å, respectively, measured by nitrogen adsorption/desorption analysis.",Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301030/),[m2] / [g],63.512,172004,DB00275,Olmesartan
,34301030,pore volume,"In addition, a nanosized porous morphology was detected for this optimized system with NS surface area of about 63.512 m2/g, pore volume and pore radius Dv(r) of 0.149 cc/g and 15.274 Å, respectively, measured by nitrogen adsorption/desorption analysis.",Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301030/),[cc] / [g],0.149,172005,DB00275,Olmesartan
,34301030,pore radius Dv(r),"In addition, a nanosized porous morphology was detected for this optimized system with NS surface area of about 63.512 m2/g, pore volume and pore radius Dv(r) of 0.149 cc/g and 15.274 Å, respectively, measured by nitrogen adsorption/desorption analysis.",Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34301030/),å,15.274,172006,DB00275,Olmesartan
,32275456,polydispersity index,"Results: The prepared lyophilized ONC containing 10% w/v mannitol showed an average particle size of 158 nm, polydispersity index of 0.37, negative zeta potential value equals 33.9 and entrapment efficiency of 90%.",Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32275456/),,0.37,173635,DB00275,Olmesartan
,32275456,zeta potential,"Results: The prepared lyophilized ONC containing 10% w/v mannitol showed an average particle size of 158 nm, polydispersity index of 0.37, negative zeta potential value equals 33.9 and entrapment efficiency of 90%.",Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32275456/),,33.9,173636,DB00275,Olmesartan
,32275456,entrapment efficiency,"Results: The prepared lyophilized ONC containing 10% w/v mannitol showed an average particle size of 158 nm, polydispersity index of 0.37, negative zeta potential value equals 33.9 and entrapment efficiency of 90%.",Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32275456/),%,90,173637,DB00275,Olmesartan
,22494992,"C(max,dn)","The dose-normalized mean C(max) and AUC(t) in the ABCC2 -24CT genotype group were higher than those in the -24CC genotype group [C(max,dn): CT 26.1 ± 6.5 (ng/mL)/mg versus CC 22.1 ± 6.7 (ng/mL)/mg, P = 0.010, AUC(t,dn): CT 178.7 ± 45.6 (hr·ng(-1)·mL(-1))/mg versus CC 149.9 ± 39.8 (hr·ng(-1)·mL(-1))/mg, P = 0.010].","Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22494992/),[ng] / [mg·ml)],26.1,176585,DB00275,Olmesartan
,22494992,"C(max,dn)","The dose-normalized mean C(max) and AUC(t) in the ABCC2 -24CT genotype group were higher than those in the -24CC genotype group [C(max,dn): CT 26.1 ± 6.5 (ng/mL)/mg versus CC 22.1 ± 6.7 (ng/mL)/mg, P = 0.010, AUC(t,dn): CT 178.7 ± 45.6 (hr·ng(-1)·mL(-1))/mg versus CC 149.9 ± 39.8 (hr·ng(-1)·mL(-1))/mg, P = 0.010].","Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22494992/),[ng] / [mg·ml)],22.1,176586,DB00275,Olmesartan
,22494992,"AUC(t,dn)","The dose-normalized mean C(max) and AUC(t) in the ABCC2 -24CT genotype group were higher than those in the -24CC genotype group [C(max,dn): CT 26.1 ± 6.5 (ng/mL)/mg versus CC 22.1 ± 6.7 (ng/mL)/mg, P = 0.010, AUC(t,dn): CT 178.7 ± 45.6 (hr·ng(-1)·mL(-1))/mg versus CC 149.9 ± 39.8 (hr·ng(-1)·mL(-1))/mg, P = 0.010].","Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22494992/),[h] / [mg·ml·ng],178.7,176587,DB00275,Olmesartan
,22494992,"AUC(t,dn)","The dose-normalized mean C(max) and AUC(t) in the ABCC2 -24CT genotype group were higher than those in the -24CC genotype group [C(max,dn): CT 26.1 ± 6.5 (ng/mL)/mg versus CC 22.1 ± 6.7 (ng/mL)/mg, P = 0.010, AUC(t,dn): CT 178.7 ± 45.6 (hr·ng(-1)·mL(-1))/mg versus CC 149.9 ± 39.8 (hr·ng(-1)·mL(-1))/mg, P = 0.010].","Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22494992/),[h] / [mg·ml·ng],149.9,176588,DB00275,Olmesartan
,22494992,"AUC(t,dn)","The difference in AUC(t,dn) between the ABCC2 -1549GG and -1549GA genotype groups was statistically significant [GG 149.0 ± 41.0 (hr·ng(-1)·mL(-1))/mg versus GA 174.1 ± 43.3 (hr·ng(-1)·mL(-1))/mg, P = 0.019].","Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22494992/),[h] / [mg·ml·ng],149.0,176589,DB00275,Olmesartan
,22494992,"AUC(t,dn)","The difference in AUC(t,dn) between the ABCC2 -1549GG and -1549GA genotype groups was statistically significant [GG 149.0 ± 41.0 (hr·ng(-1)·mL(-1))/mg versus GA 174.1 ± 43.3 (hr·ng(-1)·mL(-1))/mg, P = 0.019].","Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22494992/),[h] / [mg·ml·ng],174.1,176590,DB00275,Olmesartan
,28005442,oral bioavailability,"Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability (28%) resulting from poor aqueous solubility, presystemic metabolism and P-glycoprotein mediated efflux.","Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28005442/),%,28,177946,DB00275,Olmesartan
,28005442,zeta potential,"The optimized formulation comprised glyceryl monostearate, soya phosphatidylcholine and Tween 80 as lipid, co-emulsifier and surfactant, respectively, with an average particle size of 100 nm, PDI 0.291, zeta potential of -23.4 mV and 78% entrapment efficiency.","Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28005442/),m,23.4,177947,DB00275,Olmesartan
,16372830,CL/F,"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h).","Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372830/),[l] / [h],6.66,184255,DB00275,Olmesartan
,16372830,absorption rate constant,"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h).","Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372830/),1/[h],1.46,184256,DB00275,Olmesartan
,16372830,elimination rate constant,"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h).","Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372830/),1/[h],0.193,184257,DB00275,Olmesartan
,16372830,rate constant from the central to peripheral compartment,"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h).","Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. ","λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372830/),1/[h],0.061,184258,DB00275,Olmesartan
,16372830,rate constant,"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h).","Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372830/),1/[h],0.079,184259,DB00275,Olmesartan
,16372830,absorption lag-time,"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h).","Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16372830/),h,0.427,184260,DB00275,Olmesartan
,22820090,flux,Olmesartan medoxomil was delivered successfully across the skin with flux achieving 3.65μgcm(-2)h(-1).,Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22820090/),1/[(μgcm)^2],3.65,184278,DB00275,Olmesartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,35,184743,DB00275,Olmesartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,23,184744,DB00275,Olmesartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,31,184745,DB00275,Olmesartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184746,DB00275,Olmesartan
,19074974,biliary excretion index,"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],0.943,184747,DB00275,Olmesartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,25,184748,DB00275,Olmesartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),%,16,184749,DB00275,Olmesartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],3.39,184750,DB00275,Olmesartan
,19074974,intrinsic Cl(biliary),"The average biliary excretion index and in vitro intrinsic Cl(biliary) values of olmesartan, valsartan, pravastatin, rosuvastatin, and pitavastatin in sandwich-cultured human hepatocytes were 35, 23, 31, 25, and 16%, respectively, and 0.943, 1.20, 0.484, 3.39, and 5.48 ml/min/kg, respectively.",Use of sandwich-cultured human hepatocytes to predict biliary clearance of angiotensin II receptor blockers and HMG-CoA reductase inhibitors. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074974/),[ml] / [kg·min],5.48,184751,DB00275,Olmesartan
,28444983,bioavailability,The bioavailability of AZL is about 60% and it has a tmax of 1.5-3 hr and a half-life of approximately 11 hr.,"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),%,60,188020,DB00275,Olmesartan
,28444983,tmax,The bioavailability of AZL is about 60% and it has a tmax of 1.5-3 hr and a half-life of approximately 11 hr.,"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),h,1.5-3,188021,DB00275,Olmesartan
,28444983,half-life,The bioavailability of AZL is about 60% and it has a tmax of 1.5-3 hr and a half-life of approximately 11 hr.,"Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),h,11,188022,DB00275,Olmesartan
,28444983,IC50,"With its IC50 of 7.4 nM after 5 hr of drug washout in radioligand assays, AZL has a tighter and longer-lasting binding to the AT1 receptor by several orders of magnitude than other ARBs, which might lead to a more effective reduction in BP.","Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444983/),nM,7.4,188023,DB00275,Olmesartan
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2439,189018,DB00275,Olmesartan
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2388,189019,DB00275,Olmesartan
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2340,189020,DB00275,Olmesartan
,19659504,"AUC(ss,tau)","Mean olmesartan AUC(ss,tau) for olmesartan alone and with amlodipine were 2439 and 2388 ng h/mL and for olmesartan alone and with atenolol were 2340 and 2247 ng h/mL.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[h·ng] / [ml],2247,189021,DB00275,Olmesartan
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],465.7,189022,DB00275,Olmesartan
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],439.5,189023,DB00275,Olmesartan
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],447.4,189024,DB00275,Olmesartan
,19659504,"C(ss,max)","Corresponding olmesartan C(ss,max) values were 465.7 and 439.5 ng/mL for amlodipine, and 447.4 and 423.8 ng/mL for atenolol.",Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),[ng] / [ml],423.8,189025,DB00275,Olmesartan
,19659504,t(max),Median t(max) values for olmesartan were 1.5 h for each group in each study.,Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19659504/),h,1.5,189026,DB00275,Olmesartan
,11451211,elimination half-life,The elimination half-life was 10-15 h.,The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),h,10-15,189075,DB00275,Olmesartan
,11451211,Renal clearance,"Renal clearance (0.5-0.7 l/h) was independent of dose, accounting for approximately 9-12% of an oral dose.",The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),[l] / [h],0.5-0.7,189076,DB00275,Olmesartan
,11451211,absolute bioavailability,The absolute bioavailability of olmesartan from olmesartan medoxomil tablets was 28.6%.,The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451211/),%,28.6,189077,DB00275,Olmesartan
,21988221,effective permeability coefficient (P(eff)),The greatest value for effective permeability coefficient (P(eff)) was 11.4 × 10(-6) cm/s in the duodenum (90 μM); the lowest value was 2.9 × 10(-6) cm/s in the ileum (10 μM).,In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988221/),[cm] / [s],11.4 × 10(-6),227064,DB00275,Olmesartan
,21988221,effective permeability coefficient (P(eff)),The greatest value for effective permeability coefficient (P(eff)) was 11.4 × 10(-6) cm/s in the duodenum (90 μM); the lowest value was 2.9 × 10(-6) cm/s in the ileum (10 μM).,In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988221/),[cm] / [s],2.9 × 10(-6),227065,DB00275,Olmesartan
,21988221,self-dispersion time,"A SMEDDS formulation consisting of Capryol 90, Labrasol, and Transcutol, which has a droplet size of 200 nm and self-dispersion time of 21 s, doubled upper intestinal permeability of OLM.",In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988221/),s,21,227066,DB00275,Olmesartan
,27005906,vesicles size,"The optimum nano-invasomes formulation showed vesicles size of 83.35±3.25nm, entrapment efficiency of 65.21±2.25% and transdermal flux of 32.78±0.703 (μg/cm(2)/h) which were found in agreement with the predicted value generated by Box-Behnken design.","Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27005906/),nm,83.35,251556,DB00275,Olmesartan
,27005906,entrapment efficiency,"The optimum nano-invasomes formulation showed vesicles size of 83.35±3.25nm, entrapment efficiency of 65.21±2.25% and transdermal flux of 32.78±0.703 (μg/cm(2)/h) which were found in agreement with the predicted value generated by Box-Behnken design.","Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27005906/),%,65.21,251557,DB00275,Olmesartan
,27005906,transdermal flux,"The optimum nano-invasomes formulation showed vesicles size of 83.35±3.25nm, entrapment efficiency of 65.21±2.25% and transdermal flux of 32.78±0.703 (μg/cm(2)/h) which were found in agreement with the predicted value generated by Box-Behnken design.","Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27005906/),[μg] / [cm(2)·h],32.78,251558,DB00275,Olmesartan
,20974325,AUC(0-∞),"The mean AUC(0-∞) values for the test tablet, test capsule, and reference tablet were 3993 (1070), 3567 (850), and 3849 (872) ng/mL/h, respectively.","The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974325/),[ng] / [h·ml],3993,255182,DB00275,Olmesartan
,20974325,AUC(0-∞),"The mean AUC(0-∞) values for the test tablet, test capsule, and reference tablet were 3993 (1070), 3567 (850), and 3849 (872) ng/mL/h, respectively.","The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974325/),[ng] / [h·ml],3567,255183,DB00275,Olmesartan
,20974325,AUC(0-∞),"The mean AUC(0-∞) values for the test tablet, test capsule, and reference tablet were 3993 (1070), 3567 (850), and 3849 (872) ng/mL/h, respectively.","The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974325/),[ng] / [h·ml],3849,255184,DB00275,Olmesartan
,11361048,time to maximum plasma concentration,"The time to maximum plasma concentration of RNH-6270 after oral CS-866 administration ranged from 1.4 to 2.8 hours, and the terminal elimination half-life ranged from 12 to 18 hours.","Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361048/),h,1.4 to 2.8,271440,DB00275,Olmesartan
,11361048,terminal elimination half-life,"The time to maximum plasma concentration of RNH-6270 after oral CS-866 administration ranged from 1.4 to 2.8 hours, and the terminal elimination half-life ranged from 12 to 18 hours.","Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361048/),h,12 to 18,271441,DB00275,Olmesartan
,11361048,Absolute bioavailability,Absolute bioavailability of RNH-6270 after oral administration of CS-866 was 26%.,"Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361048/),%,26,271442,DB00275,Olmesartan
,11361048,volume of distribution,"When administered intravenously, RNH-6270 has a volume of distribution of 15 to 25 L.","Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11361048/),l,15 to 25,271443,DB00275,Olmesartan
,17060062,"AUCss,tau","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],2594.8,273249,DB00275,Olmesartan
,17060062,"AUCss,tau","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],2443.7,273250,DB00275,Olmesartan
,17060062,"Css,max","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[ng] / [ml],479.3,273251,DB00275,Olmesartan
,17060062,"Css,max","Mean AUCss,tau values for olmesartan were 2594.8 ng h/ml for olmesartan alone and 2443.7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479.3 ng/ml and 462.7 ng/ml, respectively.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[ng] / [ml],462.7,273252,DB00275,Olmesartan
,17060062,"AUCss,tau","For glibenclamide, the mean AUCss,tau values were 525.7 ng x h/ml for monotherapy and 518.7 ng x h/ml for its combination with olmesartan.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],525.7,273253,DB00275,Olmesartan
,17060062,"AUCss,tau","For glibenclamide, the mean AUCss,tau values were 525.7 ng x h/ml for monotherapy and 518.7 ng x h/ml for its combination with olmesartan.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),[h·ng] / [ml],518.7,273254,DB00275,Olmesartan
,17060062,"time to reach Css,max (tmax)","The median time to reach Css,max (tmax) for glibenclamide was shifted from 2.0 h to 1.0 h when combined with olmesartan, whereas the median tmax values for olmesartan remained unchanged at 1.5 h.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),h,2.0,273255,DB00275,Olmesartan
,17060062,"time to reach Css,max (tmax)","The median time to reach Css,max (tmax) for glibenclamide was shifted from 2.0 h to 1.0 h when combined with olmesartan, whereas the median tmax values for olmesartan remained unchanged at 1.5 h.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),h,1.0,273256,DB00275,Olmesartan
,17060062,tmax,"The median time to reach Css,max (tmax) for glibenclamide was shifted from 2.0 h to 1.0 h when combined with olmesartan, whereas the median tmax values for olmesartan remained unchanged at 1.5 h.",Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17060062/),h,1.5,273257,DB00275,Olmesartan
